Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22676957 | 0.86 | SRC (0.44) | LRRK2SRC | |
| SCHEMBL29452532 | 0.86 | SRC (0.44) | LRRK2SRC | |
| SCHEMBL28700136 | 0.80 | LRRK2 (0.43) | LRRK2DYRK1ASRCJAK2JAK1 | |
| SCHEMBL22659126 | 0.74 | DYRK1A (0.39) | LRRK2DYRK1AADORA2AADORA2BADORA1 | |
| SCHEMBL22659128 | 0.74 | DYRK1A (0.39) | LRRK2DYRK1AADORA2AADORA2BADORA1 | |
| SCHEMBL29407786 | 0.74 | DYRK1A (0.39) | LRRK2DYRK1AADORA2AADORA2BADORA1 | |
| SCHEMBL22659032 | 0.73 | BTK (0.45) | — | |
| SCHEMBL29407628 | 0.72 | SRC (0.52) | LRRK2SRC | |
| SCHEMBL22658709 | 0.72 | SRC (0.52) | LRRK2SRC | |
| SCHEMBL31399003 | 0.66 | SRC (0.41) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3968999-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | LRRK2 186/4885DYRK1A 1414/4885SRC 18/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | LRRK2 186/4885DYRK1A 1414/4885SRC 18/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | LRRK2 186/4885DYRK1A 1414/4885SRC 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.